Summary

The global tumor ablation market is projected to reach USD 1.89 billion by 2031 from USD 1.10 billion in 2026, at a CAGR of 11.4% during the forecast period. There is notable growth in the market for tumor ablation owing to the increase in the burden of cancer across the globe as well as the rise in demand for minimally invasive treatment methods. With the rising number of cases of liver, lung, kidney, bone, and prostate cancer, there is increased adoption of tumor ablation as an effective alternative or supplement to surgical treatment. Tumor ablation provides numerous benefits in clinical practice, including reduced hospital stay, quicker recovery time, minimized blood loss, reduced complications, and minimal damage to healthy tissue; thus, this procedure is ideal for people who cannot undergo surgical removal of tumors. Moreover, advances in tumor ablation technology, including radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, laser ablation, high-intensity focused ultrasound (HIFU), and irreversible electroporation (IRE), have enhanced the accuracy, safety, and effectiveness of this method. The expansion of oncology and interventional radiology centers, increasing knowledge among physicians, favorable reimbursement policies in developed countries, and investment in cancer care infrastructure facilities have been driving the adoption of tumor ablation devices and market growth. By application, the liver cancer segment is expected to have the largest market share in the tumor ablation market. The largest segment in the tumor ablation market by application is that of liver cancer since a considerable number of ablations are performed to treat both primary liver cancers and some cases of metastatic liver lesions. It has been established that tumor ablation serves as the treatment method of choice for patients with small, localized tumors where surgery and liver transplantation are contraindicated due to compromised liver functionality or other reasons. Technologies like RFA, MWA, cryoablation, and IRE are extensively used to eliminate liver tumors because they ensure tumor elimination while preserving healthy liver tissue. Also, the growth in the incidence of liver cancer around the world, increasing preference towards minimal invasiveness of the procedure, the efficacy proven by tumor ablation in case of early-stage HCC, and development of interventional oncology centers are among other factors contributing to the dominant position of the liver cancer segment in the global tumor ablation market. By end user, the hospitals & clinics segment is expected to hold the largest market share in the tumor ablation market. Hospitals and clinics constitute the highest segment of the tumor ablation market based on end-user owing to their advanced capabilities to provide comprehensive cancer care, well-equipped procedural infrastructure, and multidisciplinary oncological teams. Hospitals and clinics possess all necessary operating rooms and interventional radiology units along with trained and skilled personnel who can conduct a large number of tumor ablation procedures with ease. Hospitals and clinics treat a vast number of cancer cases that require combination therapies such as surgery, chemotherapy, radiation therapy, and ablation. Favorable reimbursement scenarios, advanced ablation technologies, and infrastructure development in the field of oncology have further boosted the adoption of tumor ablation devices in such healthcare settings. An increase in the number of minimally invasive cancer procedures conducted in hospitals and clinics has led to their increased presence in the tumor ablation market. US to grow at the highest CAGR for North America tumor ablation market. US is estimated to witness the fastest CAGR in the North American market for tumor ablation owing to factors such as increasing cases of cancer, rising number of minimally invasive procedures, and development in ablation technology. This region enjoys an advanced healthcare system, presence of top players manufacturing medical devices, and faster adoption of latest technologies such as microwave ablation, cryoablation, irreversible electroporation (IRE), and HIFU. Other factors boosting the growth of the market include investments in cancer research, increasing interventional oncology programs, and an increasing number of specialty cancer centers. Favorable reimbursement scenarios, high healthcare spending, clinical trials, and awareness among doctors and patients about the benefits of tumor ablation are other factors that will boost adoption of tumor ablation devices, making the US the fastest-growing market in North America. A breakdown of the primary participants (supply-side) for the tumor ablation market referred to for this report is provided below: • By Company Type: Tier 1–35%, Tier 2–40%, and Tier 3–25% • By Designation: C-level–45%, Director Level–35%, and Others–20% • By Region: North America–27%, Europe–25%, Asia Pacific–30%, Latin America- 8%, Middle East & Africa-10% . Prominent players in the tumor ablation market are Medtronic (Ireland), Boston Scientific Corporation (US), EDAP TMS (France), Bioventus Inc. (US), CONMED Corporation (US). Research Coverage: The report analyzes the tumor ablation market and aims to estimate the market size and future growth potential of this market based on various segments such as technology, product, procedure, application, end user, and region. The report also includes a competitive analysis of the key players in this market along with their company profiles, service offerings, recent developments, and key market strategies. Reasons to Buy the Report The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall tumor ablation market. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities. This report provides insights into the following pointers: ・ Analysis of key drivers (" Increasing global cancer incidence, Rising preference for minimally invasive procedures, Growing geriatric population, Rapid technological advancement), (High Cost of Tumor Ablation Systems and Procedures, Stringent Regulatory Approval Pathways), opportunities (Expansion of Cancer Care Centers and Hospitals, Adoption of Robotic and Al-Assisted Ablation Technologies) and challenges (Shortage of Skilled Interventional Radiologists and Oncologists, Budget Limitations in Hospitals). • Market Penetration: It includes extensive information on products offered by the major players in the global tumor ablation market. The report includes various segments in technology, product, procedure, application, end user, and region. • Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global tumor ablation market. • Market Development: Thorough knowledge and analysis of the profitable rising markets by technology, product, procedure, application, end user, and region. • Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global tumor ablation market. • Competitive Assessment: Thorough evaluation of the market shares, growth plans, product offerings, and capacities of the major competitors in the global tumor ablation market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 29
1.3 STUDY SCOPE 30
1.3.1 MARKETS COVERED AND REGIONS CONSIDERED 30
1.3.2 INCLUSIONS AND EXCLUSIONS 31
1.3.3 YEARS CONSIDERED 31
1.3.4 CURRENCY CONSIDERED 31
1.4 STAKEHOLDERS 32
1.5 SUMMARY OF CHANGES 32
2 EXECUTIVE SUMMARY 34
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 34
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & DEVELOPMENTS 35
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 36
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 37
2.5 REGIONAL SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 38
3 PREMIUM INSIGHTS 39
3.1 TUMOR ABLATION MARKET OVERVIEW 39
3.2 ASIA PACIFIC: TUMOR ABLATION MARKET, BY PRODUCT AND COUNTRY (2025) 40
3.3 TUMOR ABLATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES (2025) 41
3.4 TUMOR ABLATION MARKET, BY REGION (2024−2031) 41
3.5 TUMOR ABLATION MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES 42
4 MARKET OVERVIEW 43
4.1 INTRODUCTION 43
4.1.1 DRIVERS 43
4.1.1.1 Increasing global cancer incidence 43
4.1.1.2 Rising preference for minimally invasive procedures 44
4.1.1.3 Growing geriatric population 44
4.1.1.4 Rapid technological advancement 45
4.1.2 RESTRAINTS 45
4.1.2.1 High cost of tumor ablation systems and procedures 45
4.1.2.2 Stringent regulatory approval pathways 46
4.1.3 OPPORTUNITIES 46
4.1.3.1 Expansion of cancer care centers and hospitals 46
4.1.3.2 Adoption of robotic and AI-assisted ablation technologies 46
4.1.4 CHALLENGES 47
4.1.4.1 Shortage of skilled interventional radiologists and oncologists 47
4.1.4.2 Budget limitations in hospitals 47
4.2 UNMET NEEDS AND WHITE SPACES 48
4.2.1 UNMET NEEDS IN TUMOR ABLATION MARKET 48
4.2.2 WHITE SPACE OPPORTUNITIES 48
4.3 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 49
4.3.1 INTERCONNECTED MARKETS 50
4.3.2 CROSS-SECTOR OPPORTUNITIES MARKET 51
4.4 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 53
5 INDUSTRY TRENDS 54
5.1 PORTER’S FIVE FORCES ANALYSIS 54
5.1.1 THREAT OF NEW ENTRANTS 55
5.1.2 THREAT OF SUBSTITUTES 55
5.1.3 BARGAINING POWER OF SUPPLIERS 55
5.1.4 BARGAINING POWER OF BUYERS 55
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 55
5.2 MACROECONOMIC OUTLOOK 55
5.2.1 INTRODUCTION 55
5.2.2 GDP TRENDS AND FORECAST 56
5.2.3 TRENDS IN GLOBAL ABLATION TECHNOLOGY INDUSTRY 57
5.2.4 TRENDS IN GLOBAL INTERVENTIONAL ONCOLOGY INDUSTRY 58
5.3 SUPPLY CHAIN ANALYSIS 58
5.4 VALUE CHAIN ANALYSIS 59
5.4.1 RESEARCH & PRODUCT DEVELOPMENT 60
5.4.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING 60
5.4.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES 60
5.5 ECOSYSTEM ANALYSIS 60
5.6 PRICING ANALYSIS (2023–2025) 61
5.6.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER (2025) 61
5.6.2 AVERAGE SELLING PRICE TREND, BY REGION (2023–2025) 61
5.7 TRADE DATA ANALYSIS 62
5.7.1 IMPORT SCENARIO FOR HS CODE 9018 62
5.7.2 EXPORT SCENARIO FOR HS CODE 9018 62
5.8 KEY CONFERENCES AND EVENTS, 2026–2027 63
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 63
5.10 INVESTMENT AND FUNDING SCENARIO 64
5.11 CASE STUDY ANALYSIS 64
5.11.1 CASE STUDY 1: RADIOFREQUENCY ABLATION ANALYSIS CASE STUDY 64
5.11.2 CASE STUDY 2: RADIOFREQUENCY ABLATION ANALYSIS 64
5.11.3 CASE STUDY 3: ABLATION OF LOCALIZED RENAL TUMOR 65
5.12 IMPACT OF 2025 US TARIFFS—TUMOR ABLATION MARKET 65
5.12.1 INTRODUCTION 65
5.12.2 KEY TARIFF RATES 66
5.12.3 PRICE IMPACT ANALYSIS 66
5.12.4 IMPACT ON COUNTRIES/REGIONS 67
5.12.4.1 US 67
5.12.4.2 Europe 68
5.12.4.3 Asia Pacific 68
5.12.5 IMPACT ON END-USER INDUSTRIES 69
5.12.5.1 Hospitals & clinics 69
5.12.5.2 Cancer care centers 69
5.12.5.3 Ambulatory surgical centers and outpatient facilities 69
5.12.5.4 Interventional radiology and specialty oncology clinics 69
5.12.5.5 Academic medical centers and research institutions 69
5.12.5.6 Public and government-funded healthcare facilities 69
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 70
6.1 KEY EMERGING TECHNOLOGIES 70
6.1.1 RADIOFREQUENCY ABLATION (RFA) 70
6.1.2 MICROWAVE ABLATION (MWA) 70
6.1.3 HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU) 70
6.2 COMPLEMENTARY TECHNOLOGIES 70
6.2.1 ROBOTIC-ASSISTED NAVIGATION 70
6.2.2 AI-ASSISTED TREATMENT PLANNING 70
6.3 ADJACENT TECHNOLOGIES 71
6.3.1 TUMOR EMBOLIZATION 71
6.4 TECHNOLOGY/PRODUCT ROADMAP 71
6.4.1 SHORT-TERM (2025–2027) | FOUNDATION & EARLY COMMERCIALIZATION 71
6.4.2 MID-TERM (2027–2030) | EXPANSION & STANDARDIZATION 72
6.4.3 LONG-TERM (2030–2035+) | MASS COMMERCIALIZATION & DISRUPTION 74
6.5 PATENT ANALYSIS 76
6.6 FUTURE APPLICATIONS OF TUMOR ABLATION 77
6.7 IMPACT OF AI/GEN AI—TUMOR ABLATION MARKET 78
6.7.1 TOP USE CASES AND MARKET POTENTIAL 80
6.7.2 BEST PRACTICES IN TUMOR ABLATION PROCESSING 81
6.7.3 CASE STUDIES OF AI IMPLEMENTATION IN TUMOR ABLATION MARKET 82
6.7.4 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS 82
6.7.5 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN TUMOR ABLATION MARKET 84
7 REGULATORY LANDSCAPE 86
7.1 REGIONAL REGULATIONS AND COMPLIANCE 86
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
7.1.2 REGULATORY FRAMEWORK 86
7.1.2.1 North America 86
7.1.2.1.1 US 86
7.1.2.1.2 Canada 88
7.1.2.2 Europe 89
7.1.2.3 Asia Pacific 91
7.1.2.3.1 Japan 91
7.1.2.3.2 China 93
7.1.2.3.3 India 94
7.1.2.4 Latin America 95
7.1.2.4.1 Brazil 95
7.1.3 INDUSTRY STANDARDS 95
7.2 CERTIFICATIONS, LABELING, ECO-STANDARDS 96
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 98
8.1 DECISION-MAKING PROCESS 98
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 98
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 98
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 100
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 101
8.5 MARKET PROFITABILITY 102
8.5.1 REVENUE POTENTIAL 102
8.5.2 COST DYNAMICS 102
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 103
9 TUMOR ABLATION MARKET, BY TECHNOLOGY 105
9.1 INTRODUCTION 106
9.2 RADIOFREQUENCY ABLATION 106
9.2.1 LOW COST OF RADIOFREQUENCY ABLATION TO CONTRIBUTE TO MARKET GROWTH 106
9.3 MICROWAVE ABLATION 107
9.3.1 ADVANTAGES OF MICROWAVE ABLATION TO BOOST MARKET GROWTH 107
9.4 CRYOABLATION 108
9.4.1 HIGH SAFETY AND EFFICACY OF CRYOABLATION TO BOOST MARKET 108
9.5 IRREVERSIBLE ELECTROPORATION 108
9.5.1 NON-THERMAL ABLATION AND PRECISION TREATMENT CAPABILITIES OF IRREVERSIBLE ELECTROPORATION TO DRIVE MARKET GROWTH 108
9.6 OTHER TECHNOLOGIES 109
10 TUMOR ABLATION MARKET, BY PRODUCT TYPE 111
10.1 INTRODUCTION 112
10.2 SYSTEMS 112
10.2.1 RADIOFREQUENCY ABLATION SYSTEMS 113
10.2.1.1 Advancements In Radiofrequency Ablation Systems To Enhance Precision and Treatment Efficacy 113
10.2.2 MICROWAVE ABLATION SYSTEMS 113
10.2.2.1 Advancements in high-power energy delivery and larger ablation zones to drive microwave ablation systems market growth 113
10.2.3 IRREVERSIBLE ELECTROPORATION SYSTEMS 114
10.2.3.1 Non-thermal ablation and precision treatment capabilities of irreversible electroporation to drive market growth 114
10.2.4 CRYOABLATION SYSTEMS 115
10.2.4.1 Advancements in controlled freezing and ablation-zone visualization to drive cryoablation systems market growth 115
10.2.5 OTHER SYSTEMS 115
10.3 CONSUMABLES & ACCESSORIES 116
10.4 PROBES/ELECTRODES 117
10.4.1 RADIOFREQUENCY ABLATION PROBES 118
10.4.1.1 Advancements in RFA probe design and cooling technologies to drive market growth 118
10.4.2 MICROWAVE ABLATION PROBES 118
10.4.2.1 Advancements in microwave antenna design and energy delivery to support market growth 118
10.4.3 OTHER PROBES/ELECTRODES 119
10.5 OTHER CONSUMABLES & ACCESSORIES 119
11 TUMOR ABLATION MARKET, BY PROCEDURE 120
11.1 INTRODUCTION 121
11.2 SURGICAL ABLATION 121
11.2.1 RISING UTILIZATION OF SURGICAL ABLATION IN END-USER FACILITIES TO PROPEL MARKET 121
11.3 LAPAROSCOPIC ABLATION 122
11.3.1 IMPROVED SUCCESS RATE AND REAL-TIME VISUALIZATION TO BOOST DEMAND 122
11.4 PERCUTANEOUS ABLATION 123
11.4.1 SHORTER RECOVERY TIME AND COST-EFFECTIVENESS OF PROCEDURE TO DRIVE SEGMENT 123
12 TUMOR ABLATION MARKET, BY APPLICATION 124
12.1 INTRODUCTION 125
12.2 LIVER CANCER 125
12.2.1 PROMISING OUTCOMES OF ABLATION IN TREATING HCC TO DRIVE MARKET 125
12.3 LUNG CANCER 126
12.3.1 RISING INCIDENCE OF LUNG CANCER TO FUEL MARKET 126
12.4 KIDNEY CANCER 127
12.4.1 RISING PREVALENCE OF KIDNEY CANCER AND MINIMAL DAMAGE TO HEALTHY TISSUE TO DRIVE ADOPTION 127
12.5 BONE CANCER 128
12.5.1 RISING USE OF ABLATION TECHNIQUES TO TREAT OSTEOID OSTEOMA TO BOOST GROWTH 128
12.6 OTHER APPLICATIONS 129
13 TUMOR ABLATION MARKET, BY END USER 130
13.1 INTRODUCTION 131
13.2 HOSPITALS & CLINICS 131
13.2.1 INCREASING ADOPTION OF ADVANCED TUMOR ABLATION SYSTEMS TO PROPEL MARKET 131
13.3 CANCER CARE CENTERS 132
13.3.1 GROWING ESTABLISHMENT OF CANCER CARE CENTERS TO FUEL MARKET 132
13.4 AMBULATORY SURGERY CENTERS 133
13.4.1 SHIFT TOWARD MINIMALLY INVASIVE AND OUTPATIENT PROCEDURES TO DRIVE MARKET 133
13.5 OTHER END USERS 133
14 TUMOR ABLATION MARKET, BY REGION 135
14.1 INTRODUCTION 136
14.2 NORTH AMERICA 136
14.2.1 US 140
14.2.1.1 Rising prevalence of cancer to propel market growth 140
14.2.2 CANADA 143
14.2.2.1 Growing burden of cancer to support market growth 143
14.3 EUROPE 146
14.3.1 GERMANY 150
14.3.1.1 Highly developed healthcare infrastructure and rising disease incidence to ensure strong growth prospects 150
14.3.2 FRANCE 152
14.3.2.1 Growing geriatric population to support market growth in France 152
14.3.3 UK 155
14.3.3.1 Growing target patient population to support market growth in UK 155
14.3.4 ITALY 158
14.3.4.1 Rising awareness to support market growth 158
14.3.5 SPAIN 161
14.3.5.1 Increasing government funding for research to support market growth 161
14.3.6 REST OF EUROPE 164
14.4 ASIA PACIFIC 167
14.4.1 JAPAN 171
14.4.1.1 Presence of universal healthcare reimbursement scenario to drive market growth 171
14.4.2 CHINA 174
14.4.2.1 Increasing patient pool and government initiatives for healthcare development to fuel market growth 174
14.4.3 INDIA 177
14.4.3.1 Ongoing modernization and infrastructure development in India to support market growth 177
14.4.4 AUSTRALIA 180
14.4.4.1 Rising research investments and awareness campaigns to support market growth 180
14.4.5 SOUTH KOREA 183
14.4.5.1 Rising R&D and promising clinical trials to positively impact market growth 183
14.4.6 REST OF ASIA PACIFIC 186
14.5 LATIN AMERICA 189
14.5.1 BRAZIL 193
14.5.1.1 Modernization of healthcare facilities in Brazil to boost market 193
14.5.2 MEXICO 196
14.5.2.1 Availability of advanced care and increasing awareness programs to fuel market growth in Mexico 196
14.5.3 REST OF LATIN AMERICA 199
14.6 MIDDLE EAST & AFRICA 202
14.6.1 GCC COUNTRIES 206
14.6.1.1 Increasing investments in oncology infrastructure and adoption of advanced minimally invasive treatment technologies to drive market growth 206
14.6.2 REST OF MIDDLE EAST AND AFRICA 209
15 COMPETITIVE LANDSCAPE 213
15.1 INTRODUCTION 213
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 213
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TUMOR ABLATION MARKET 213
15.3 REVENUE ANALYSIS, 2021–2025 215
15.4 MARKET SHARE ANALYSIS, 2025 216
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 218
15.5.1 STARS 218
15.5.2 EMERGING LEADERS 218
15.5.3 PERVASIVE PLAYERS 218
15.5.4 PARTICIPANTS 218
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 220
15.5.5.1 Company footprint 220
15.5.5.2 Region footprint 221
15.5.5.3 Technology footprint 222
15.5.5.4 Product type footprint 223
15.5.5.5 Procedure footprint 224
15.5.5.6 Application footprint 225
15.5.5.7 End-user footprint 226
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 227
15.6.1 PROGRESSIVE COMPANIES 227
15.6.2 DYNAMIC COMPANIES 227
15.6.3 STARTING BLOCKS 227
15.6.4 RESPONSIVE COMPANIES 227
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 228
15.7 COMPANY VALUATION AND FINANCIAL METRICS 229
15.7.1 FINANCIAL METRICS 229
15.7.2 COMPANY VALUATION 230
15.7.3 BRAND/PRODUCT COMPARISON 231
15.8 COMPETITIVE SCENARIO 232
15.8.1 PRODUCT & SERVICE LAUNCHES AND APPROVALS 232
15.8.2 DEALS 232
15.8.3 EXPANSIONS 233
16 COMPANY PROFILES 234
16.1 KEY PLAYERS 234
16.1.1 MEDTRONIC 234
16.1.1.1 Business overview 234
16.1.1.2 Products offered 235
16.1.1.3 Recent developments 236
16.1.1.3.1 Product approvals 236
16.1.1.4 MnM view 236
16.1.1.4.1 Key strengths 236
16.1.1.4.2 Strategic choices 236
16.1.1.4.3 Weaknesses and competitive threats 237
16.1.2 BOSTON SCIENTIFIC CORPORATION 238
16.1.2.1 Business overview 238
16.1.2.2 Products offered 239
16.1.2.3 MnM view 240
16.1.2.3.1 Key strengths 240
16.1.2.3.2 Strategic choices made 240
16.1.2.3.3 Weaknesses and competitive threats 240
16.1.3 EDAP TMS S.A. 241
16.1.3.1 Business overview 241
16.1.3.2 Products offered 242
16.1.3.3 MnM view 242
16.1.3.3.1 Key strengths 242
16.1.3.3.2 Strategic choices made 243
16.1.3.3.3 Weaknesses and competitive threats 243
16.1.4 BIOVENTUS INC. 244
16.1.4.1 Business overview 244
16.1.4.2 Products offered 245
16.1.4.3 Recent developments 245
16.1.4.3.1 Deals 245
16.1.4.4 MnM view 245
16.1.4.4.1 Key strengths 245
16.1.4.4.2 Strategic choices made 245
16.1.4.4.3 Weaknesses and competitive threats 246
16.1.5 CONMED CORPORATION 247
16.1.5.1 Business overview 247
16.1.5.2 Products offered 248
16.1.5.3 MnM view 249
16.1.5.3.1 Key strengths 249
16.1.5.3.2 Strategic choices made 249
16.1.5.3.3 Weaknesses and competitive threats 249
16.1.6 ICECURE MEDICAL LTD. 250
16.1.6.1 Business overview 250
16.1.6.2 Products offered 251
16.1.6.3 Recent developments 252
16.1.6.3.1 Product approvals 252
16.1.6.3.2 Deals 252
16.1.6.3.3 Expansions 253
16.1.7 ANGIODYNAMICS, INC. 254
16.1.7.1 Business overview 254
16.1.7.2 Products offered 255
16.1.7.3 Recent developments 256
16.1.7.3.1 Product launches 256
16.1.7.3.2 Expansions 256
16.1.7.3.3 Deals 256
16.1.8 VARIAN MEDICAL SYSTEMS, INC. 257
16.1.8.1 Business overview 257
16.1.8.2 Products offered 258
16.1.8.3 Recent developments 258
16.1.8.3.1 Product launches 258
16.1.8.3.2 Deals 258
16.1.9 STRYKER 260
16.1.9.1 Business overview 260
16.1.9.2 Products offered 261
16.1.9.3 Recent developments 262
16.1.9.3.1 Product approvals 262
16.1.9.3.2 Expansions 262
16.1.10 CANYON MEDICAL INC. 263
16.1.10.1 Business overview 263
16.1.10.2 Products offered 263
16.1.11 CHONGQING HAIFU MEDICAL TECHNOLOGY CO., LTD. 264
16.1.11.1 Business overview 264
16.1.11.2 Products offered 264
16.1.12 MERIT MEDICAL SYSTEMS, INC. 265
16.1.12.1 Business overview 265
16.1.12.2 Products offered 266
16.1.12.3 Recent developments 266
16.1.12.3.1 Deals 266
16.1.13 BAIRD MEDICAL INVESTMENT HOLDINGS LTD. 267
16.1.13.1 Business overview 267
16.1.13.2 Products offered 268
16.1.13.3 Recent developments 269
16.1.13.3.1 Expansions 269
16.1.14 QUANTUM SURGICAL 270
16.1.14.1 Business overview 270
16.1.14.2 Products offered 270
16.1.14.3 Recent developments 270
16.1.14.3.1 Deals 270
16.1.15 THERACLION 271
16.1.15.1 Business overview 271
16.1.15.2 Products offered 271
16.2 OTHER PLAYERS 272
16.2.1 RF MEDICAL CO., LTD. 272
16.2.2 MINIMAX MEDICAL HOLDING GROUP 273
16.2.3 MERMAID MEDICAL 274
16.2.4 MONTERIS 274
16.2.5 SONABLATE CORP. 275
16.2.6 ECO MEDICAL 276
16.2.7 SURGNOVA 276
16.2.8 STARMED CO., LTD. 278
16.2.9 CREO MEDICAL 279
16.2.10 MEDSPHERE SHANGHAI (SUBSIDIARY OF MEDSPHERE INTERNATIONAL, INC.) 280
17 RESEARCH METHODOLOGY 281
17.1 RESEARCH DATA 281
17.1.1 SECONDARY DATA 281
17.1.1.1 Key data from secondary sources 282
17.1.2 PRIMARY DATA 282
17.1.2.1 Key data from primary sources 283
17.1.2.2 Key industry insights 284
17.2 MARKET SIZE ESTIMATION 284
17.2.1 BOTTOM-UP APPROACH 284
17.2.2 TOP-DOWN APPROACH 285
17.2.3 BASE NUMBER ESTIMATION 285
17.3 MARKET FORECAST APPROACH 287
17.4 MARKET BREAKDOWN AND DATA TRIANGULATION 289
17.5 ASSUMPTIONS 289
17.5.1 MARKET SHARE ASSUMPTIONS 289
17.5.2 RESEARCH ASSUMPTIONS 290
17.6 FACTOR ANALYSIS 290
17.7 RISK ASSESSMENT 291
17.8 METHODOLOGY-RELATED LIMITATIONS 291
18 APPENDIX 292
18.1 DISCUSSION GUIDE 292
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 296
18.3 CUSTOMIZATION OPTIONS 298
18.4 RELATED REPORTS 298
18.5 AUTHOR DETAILS 299

ページTOPに戻る

List of Tables/Graphs

TABLE 1 TUMOR ABLATION MARKET: INCLUSIONS AND EXCLUSIONS 31.
TABLE 2 ESTIMATED GERIATRIC POPULATION, BY REGION, 2023 VS. 2050 (IN MILLIONS) 45.
TABLE 3 TUMOR ABLATION MARKET: CURRENT UNMET NEEDS 48.
TABLE 4 TUMOR ABLATION MARKET: PORTER’S FIVE FORCES ANALYSIS 54.
TABLE 5 GDP PERCENTAGE CHANGE IN KEY COUNTRIES, 2021–2030 56.
TABLE 6 AVERAGE SELLING PRICE TREND OF ABLATION SYSTEMS, BY KEY PLAYER, 2025 (USD MILLION) 61.
TABLE 7 AVERAGE SELLING PRICE TREND OF ABLATION SYSTEMS, BY REGION, 2023–2025 (USD) 61.
TABLE 8 IMPORT DATA FOR TUMOR ABLATION PRODUCTS (HS CODE 9018), BY COUNTRY, 2021–2025 (USD THOUSANDS) 62.
TABLE 9 EXPORT DATA FOR TUMOR ABLATION PRODUCTS (HS CODE 9018), BY COUNTRY, 2021–2025 (USD THOUSANDS) 62.
TABLE 10 TUMOR ABLATION MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS (2026-2027) 63.
TABLE 11 US ADJUSTED RECIPROCAL TARIFF RATES 66.
TABLE 12 KEY PRODUCT-RELATED TARIFFS EFFECTIVE FOR TUMOR ABLATION 66.
TABLE 13 TUMOR ABLATION MARKET: CASE STUDIES RELATED TO AI IMPLEMENTATION 82.
TABLE 14 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS 82.
TABLE 15 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86.
TABLE 16 US FDA: MEDICAL DEVICE CLASSIFICATION 86.
TABLE 17 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 87.
TABLE 18 US: CLASSIFICATION OF ABLATION DEVICES 88.
TABLE 19 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 88.
TABLE 20 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA) 92.
TABLE 21 CHINA: CLASSIFICATION OF MEDICAL DEVICES 93.
TABLE 22 GLOBAL STANDARDS IN TUMOR ABLATION MARKET 95.
TABLE 23 CERTIFICATIONS, LABELING, ECO-STANDARDS IN TUMOR ABLATION MARKET 96.
TABLE 24 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 99.
TABLE 25 KEY BUYING CRITERIA FOR TUMOR ABLATION SYSTEMS 100.
TABLE 26 TUMOR ABLATION MARKET: UNMET NEEDS/END-USER EXPECTATIONS 101.
TABLE 27 TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 106.
TABLE 28 RADIOFREQUENCY ABLATION MARKET, BY REGION, 2024–2031 (USD MILLION) 107.
TABLE 29 MICROWAVE ABLATION MARKET, BY REGION, 2024–2031 (USD MILLION) 107.
TABLE 30 CRYOABLATION MARKET, BY REGION, 2024–2031 (USD MILLION) 108.
TABLE 31 IRREVERSIBLE ELECTROPORATION MARKET, BY REGION, 2024–2031 (USD MILLION) 109.
TABLE 32 OTHER TUMOR ABLATION TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 110.
TABLE 33 TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 112.
TABLE 34 TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 112.
TABLE 35 RADIOFREQUENCY ABLATION SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 113.
TABLE 36 MICROWAVE ABLATION SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 114.
TABLE 37 IRREVERSIBLE ELECTROPORATION SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 114.
TABLE 38 CRYOABLATION SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 115.
TABLE 39 OTHER TUMOR ABLATION SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 116.
TABLE 40 TUMOR ABLATION SYSTEMS MARKET, BY REGION, 2024–2031 (MILLION UNITS) 116.
TABLE 41 TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 117.
TABLE 42 TUMOR ABLATION PROBES/ELECTRODES MARKET, BY REGION, 2024–2031 (USD MILLION) 117.
TABLE 43 RADIOFREQUENCY ABLATION PROBES MARKET, BY REGION, 2024–2031 (USD MILLION) 118.
TABLE 44 MICROWAVE ABLATION PROBES MARKET, BY REGION, 2024–2031 (USD MILLION) 118.
TABLE 45 OTHER TUMOR ABLATION PROBES/ELECTRODES MARKET, BY REGION, 2024–2031 (USD MILLION) 119.
TABLE 46 OTHER TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY REGION, 2024–2031 (USD MILLION) 119.
TABLE 47 TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 121.
TABLE 48 SURGICAL ABLATION MARKET, BY REGION, 2024–2031 (USD MILLION) 122.
TABLE 49 LAPAROSCOPIC ABLATION MARKET, BY REGION, 2024–2031 (USD MILLION) 122.
TABLE 50 PERCUTANEOUS ABLATION MARKET, BY REGION, 2024–2031 (USD MILLION) 123.
TABLE 51 TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 125.
TABLE 52 TUMOR ABLATION MARKET FOR LIVER CANCER, BY REGION, 2024–2031 (USD MILLION) 126.
TABLE 53 TUMOR ABLATION MARKET FOR LUNG CANCER, BY REGION, 2024–2031 (USD MILLION) 127.
TABLE 54 TUMOR ABLATION MARKET FOR KIDNEY CANCER, BY REGION, 2024–2031 (USD MILLION) 128.
TABLE 55 TUMOR ABLATION MARKET FOR BONE CANCER, BY REGION, 2024–2031 (USD MILLION) 128.
TABLE 56 TUMOR ABLATION MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 129.
TABLE 57 TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 131.
TABLE 58 TUMOR ABLATION MARKET FOR HOSPITALS & CLINICS, BY REGION, 2024–2031 (USD MILLION) 132.
TABLE 59 TUMOR ABLATION MARKET FOR CANCER CARE CENTERS, BY REGION, 2024–2031 (USD MILLION) 132.
TABLE 60 TUMOR ABLATION MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2024–2031 (USD MILLION) 133.
TABLE 61 TUMOR ABLATION MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 134.
TABLE 62 TUMOR ABLATION MARKET, BY REGION, 2024–2031 (USD MILLION) 136.
TABLE 63 NORTH AMERICA: TUMOR ABLATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137.
TABLE 64 NORTH AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 138.
TABLE 65 NORTH AMERICA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 138.
TABLE 66 NORTH AMERICA: TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 138.
TABLE 67 NORTH AMERICA: TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 139.
TABLE 68 NORTH AMERICA: TUMOR ABLATION PROBES/ELECTRODES MARKET, BY TYPE, 2024–2031 (USD MILLION) 139.
TABLE 69 NORTH AMERICA: TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 139.
TABLE 70 NORTH AMERICA: TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 140.
TABLE 71 NORTH AMERICA: TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 140.
TABLE 72 US: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 141.
TABLE 73 US: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 141.
TABLE 74 US: TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 141.
TABLE 75 US: TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 142.
TABLE 76 US: TUMOR ABLATION PROBES/ELECTRODES MARKET, BY TYPE, 2024–2031 (USD MILLION) 142.
TABLE 77 US: TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 142.
TABLE 78 US: TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 143.
TABLE 79 US: TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 143.
TABLE 80 CANADA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 144.
TABLE 81 CANADA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 144.
TABLE 82 CANADA: TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 144.
TABLE 83 CANADA: TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 145.
TABLE 84 CANADA: TUMOR ABLATION PROBES/ELECTRODES MARKET, BY TYPE, 2024–2031 (USD MILLION) 145.
TABLE 85 CANADA: TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 145.
TABLE 86 CANADA: TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 146.
TABLE 87 CANADA: TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 146.
TABLE 88 EUROPE: TUMOR ABLATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147.
TABLE 89 EUROPE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 147.
TABLE 90 EUROPE: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 147.
TABLE 91 EUROPE: TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 148.
TABLE 92 EUROPE: TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 148.
TABLE 93 EUROPE: TUMOR ABLATION PROBES/ELECTRODES MARKET, BY TYPE, 2024–2031 (USD MILLION) 148.
TABLE 94 EUROPE: TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 149.
TABLE 95 EUROPE: TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 149.
TABLE 96 EUROPE: TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 149.
TABLE 97 GERMANY: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 150.
TABLE 98 GERMANY: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 150.
TABLE 99 GERMANY: TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 151.
TABLE 100 GERMANY: TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 151.
TABLE 101 GERMANY: TUMOR ABLATION PROBES/ELECTRODES MARKET, BY TYPE, 2024–2031 (USD MILLION) 151.
TABLE 102 GERMANY: TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 152.
TABLE 103 GERMANY: TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 152.
TABLE 104 GERMANY: TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 152.
TABLE 105 FRANCE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 153.
TABLE 106 FRANCE: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 153.
TABLE 107 FRANCE: TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 153.
TABLE 108 FRANCE: TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 154.
TABLE 109 FRANCE: TUMOR ABLATION PROBES/ELECTRODES MARKET, BY TYPE, 2024–2031 (USD MILLION) 154.
TABLE 110 FRANCE: TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 154.
TABLE 111 FRANCE: TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 155.
TABLE 112 FRANCE: TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 155.
TABLE 113 UK: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 156.
TABLE 114 UK: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 156.
TABLE 115 UK: TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 156.
TABLE 116 UK: TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 157.
TABLE 117 UK: TUMOR ABLATION PROBES/ELECTRODES MARKET, BY TYPE, 2024–2031 (USD MILLION) 157.
TABLE 118 UK: TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 157.
TABLE 119 UK: TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 158.
TABLE 120 UK: TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 158.
TABLE 121 ITALY: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 159.
TABLE 122 ITALY: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 159.
TABLE 123 ITALY: TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 159.
TABLE 124 ITALY: TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 160.
TABLE 125 ITALY: TUMOR ABLATION PROBES/ELECTRODES MARKET, BY TYPE, 2024–2031 (USD MILLION) 160.
TABLE 126 ITALY: TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 160.
TABLE 127 ITALY: TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 161.
TABLE 128 ITALY: TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 161.
TABLE 129 SPAIN: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 162.
TABLE 130 SPAIN: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 162.
TABLE 131 SPAIN: TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 162.
TABLE 132 SPAIN: TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 163.
TABLE 133 SPAIN: TUMOR ABLATION PROBES/ELECTRODES MARKET, BY TYPE, 2024–2031 (USD MILLION) 163.
TABLE 134 SPAIN: TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 163.
TABLE 135 SPAIN: TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 164.
TABLE 136 SPAIN: TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 164.
TABLE 137 REST OF EUROPE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 165.
TABLE 138 REST OF EUROPE: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 165.
TABLE 139 REST OF EUROPE: TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 165.
TABLE 140 REST OF EUROPE: TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 166.
TABLE 141 REST OF EUROPE: TUMOR ABLATION PROBES/ELECTRODES MARKET, BY TYPE, 2024–2031 (USD MILLION) 166.
TABLE 142 REST OF EUROPE: TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 166.
TABLE 143 REST OF EUROPE: TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 167.
TABLE 144 REST OF EUROPE: TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 167.
TABLE 145 ASIA PACIFIC: TUMOR ABLATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 168.
TABLE 146 ASIA PACIFIC: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 169.
TABLE 147 ASIA PACIFIC: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 169.
TABLE 148 ASIA PACIFIC: TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 169.
TABLE 149 ASIA PACIFIC: TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 170.
TABLE 150 ASIA PACIFIC: TUMOR ABLATION PROBES/ELECTRODES MARKET, BY TYPE, 2024–2031 (USD MILLION) 170.
TABLE 151 ASIA PACIFIC: TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 170.
TABLE 152 ASIA PACIFIC: TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 171.
TABLE 153 ASIA PACIFIC: TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 171.
TABLE 154 JAPAN: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 172.
TABLE 155 JAPAN: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 172.
TABLE 156 JAPAN: TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 172.
TABLE 157 JAPAN: TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 173.
TABLE 158 JAPAN: TUMOR ABLATION PROBES/ELECTRODES MARKET, BY TYPE, 2024–2031 (USD MILLION) 173.
TABLE 159 JAPAN: TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 173.
TABLE 160 JAPAN: TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 174.
TABLE 161 JAPAN: TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 174.
TABLE 162 CHINA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 175.
TABLE 163 CHINA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 175.
TABLE 164 CHINA: TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 175.
TABLE 165 CHINA: TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 176.
TABLE 166 CHINA: TUMOR ABLATION PROBES/ELECTRODES MARKET, BY TYPE, 2024–2031 (USD MILLION) 176.
TABLE 167 CHINA: TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 176.
TABLE 168 CHINA: TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 177.
TABLE 169 CHINA: TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 177.
TABLE 170 INDIA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 178.
TABLE 171 INDIA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 178.
TABLE 172 INDIA: TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 178.
TABLE 173 INDIA: TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 179.
TABLE 174 INDIA: TUMOR ABLATION PROBES/ELECTRODES MARKET, BY TYPE, 2024–2031 (USD MILLION) 179.
TABLE 175 INDIA: TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 179.
TABLE 176 INDIA: TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 180.
TABLE 177 INDIA: TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 180.
TABLE 178 AUSTRALIA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 181.
TABLE 179 AUSTRALIA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 181.
TABLE 180 AUSTRALIA: TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 181.
TABLE 181 AUSTRALIA: TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 182.
TABLE 182 AUSTRALIA: TUMOR ABLATION PROBES/ELECTRODES MARKET, BY TYPE, 2024–2031 (USD MILLION) 182.
TABLE 183 AUSTRALIA: TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 182.
TABLE 184 AUSTRALIA: TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 183.
TABLE 185 AUSTRALIA: TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 183.
TABLE 186 SOUTH KOREA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 184.
TABLE 187 SOUTH KOREA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 184.
TABLE 188 SOUTH KOREA: TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 184.
TABLE 189 SOUTH KOREA: TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 185.
TABLE 190 SOUTH KOREA: TUMOR ABLATION PROBES/ELECTRODES MARKET, BY TYPE, 2024–2031 (USD MILLION) 185.
TABLE 191 SOUTH KOREA: TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 185.
TABLE 192 SOUTH KOREA: TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 186.
TABLE 193 SOUTH KOREA: TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 186.
TABLE 194 REST OF ASIA PACIFIC: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 187.
TABLE 195 REST OF ASIA PACIFIC: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 187.
TABLE 196 REST OF ASIA PACIFIC: TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 187.
TABLE 197 REST OF ASIA PACIFIC: TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 188.
TABLE 198 REST OF ASIA PACIFIC: TUMOR ABLATION PROBES/ELECTRODES MARKET, BY TYPE, 2024–2031 (USD MILLION) 188.
TABLE 199 REST OF ASIA PACIFIC: TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 188.
TABLE 200 REST OF ASIA PACIFIC: TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 189.
TABLE 201 REST OF ASIA PACIFIC: TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 189.
TABLE 202 LATIN AMERICA: TUMOR ABLATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 190.
TABLE 203 LATIN AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 190.
TABLE 204 LATIN AMERICA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 191.
TABLE 205 LATIN AMERICA: TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 191.
TABLE 206 LATIN AMERICA: TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 191.
TABLE 207 LATIN AMERICA: TUMOR ABLATION PROBES/ELECTRODES MARKET, BY TYPE, 2024–2031 (USD MILLION) 192.
TABLE 208 LATIN AMERICA: TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 192.
TABLE 209 LATIN AMERICA: TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 192.
TABLE 210 LATIN AMERICA: TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 193.
TABLE 211 BRAZIL: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 193.
TABLE 212 BRAZIL: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 194.
TABLE 213 BRAZIL: TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 194.
TABLE 214 BRAZIL: TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 194.
TABLE 215 BRAZIL: TUMOR ABLATION PROBES/ELECTRODES MARKET, BY TYPE, 2024–2031 (USD MILLION) 195.
TABLE 216 BRAZIL: TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 195.
TABLE 217 BRAZIL: TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 195.
TABLE 218 BRAZIL: TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 196.
TABLE 219 MEXICO: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 196.
TABLE 220 MEXICO: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 197.
TABLE 221 MEXICO: TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 197.
TABLE 222 MEXICO: TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 197.
TABLE 223 MEXICO: TUMOR ABLATION PROBES/ELECTRODES MARKET, BY TYPE, 2024–2031 (USD MILLION) 198.
TABLE 224 MEXICO: TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 198.
TABLE 225 MEXICO: TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 198.
TABLE 226 MEXICO: TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 199.
TABLE 227 REST OF LATIN AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 199.
TABLE 228 REST OF LATIN AMERICA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 200.
TABLE 229 REST OF LATIN AMERICA: TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 200.
TABLE 230 REST OF LATIN AMERICA: TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 200.
TABLE 231 REST OF LATIN AMERICA: TUMOR ABLATION PROBES/ELECTRODES MARKET, BY TYPE, 2024–2031 (USD MILLION) 201.
TABLE 232 REST OF LATIN AMERICA: TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 201.
TABLE 233 REST OF LATIN AMERICA: TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 201.
TABLE 234 REST OF LATIN AMERICA: TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 202.
TABLE 235 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY REGION, 2024–2031 (USD MILLION) 203.
TABLE 236 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 203.
TABLE 237 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 203.
TABLE 238 MIDDLE EAST & AFRICA: TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 204.
TABLE 239 MIDDLE EAST & AFRICA: TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 204.
TABLE 240 MIDDLE EAST & AFRICA: TUMOR ABLATION PROBES/ELECTRODES MARKET, BY TYPE, 2024–2031 (USD MILLION) 204.
TABLE 241 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 205.
TABLE 242 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 205.
TABLE 243 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 205.
TABLE 244 REST OF GCC COUNTRIES: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 206.
TABLE 245 REST OF GCC COUNTRIES: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 207.
TABLE 246 REST OF GCC COUNTRIES: TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 207.
TABLE 247 REST OF GCC COUNTRIES: TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 207.
TABLE 248 REST OF GCC COUNTRIES: TUMOR ABLATION PROBES/ELECTRODES MARKET, BY TYPE, 2024–2031 (USD MILLION) 208.
TABLE 249 REST OF GCC COUNTRIES: TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 208.
TABLE 250 REST OF GCC COUNTRIES: TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 208.
TABLE 251 REST OF GCC COUNTRIES: TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 209.
TABLE 252 REST OF MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 210.
TABLE 253 REST OF MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 210.
TABLE 254 REST OF MIDDLE EAST & AFRICA: TUMOR ABLATION SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 210.
TABLE 255 REST OF MIDDLE EAST & AFRICA: TUMOR ABLATION CONSUMABLES & ACCESSORIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 211.
TABLE 256 REST OF MIDDLE EAST & AFRICA: TUMOR ABLATION PROBES/ELECTRODES MARKET, BY TYPE, 2024–2031 (USD MILLION) 211.
TABLE 257 REST OF MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 211.
TABLE 258 REST OF MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 212.
TABLE 259 REST OF MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY END USER, 2024–2031 (USD MILLION) 212.
TABLE 260 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN TUMOR ABLATION MARKET 213.
TABLE 261 TUMOR ABLATION MARKET: DEGREE OF COMPETITION 216.
TABLE 262 TUMOR ABLATION MARKET: REGION FOOTPRINT 221.
TABLE 263 TUMOR ABLATION MARKET: TECHNOLOGY FOOTPRINT 222.
TABLE 264 TUMOR ABLATION MARKET: PRODUCT FOOTPRINT 223.
TABLE 265 TUMOR ABLATION MARKET: PROCEDURE FOOTPRINT 224.
TABLE 266 TUMOR ABLATION MARKET: APPLICATION FOOTPRINT 225.
TABLE 267 TUMOR ABLATION MARKET: END-USER FOOTPRINT 226.
TABLE 268 TUMOR ABLATION MARKET: DETAILED LIST OF KEY STARTUPS/SMES 228.
TABLE 269 TUMOR ABLATION MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 229.
TABLE 270 TUMOR ABLATION MARKET: PRODUCT & SERVICE LAUNCHES AND APPROVALS, JANUARY 2021– MAY 2026 232.
TABLE 271 TUMOR ABLATION MARKET: DEALS, JANUARY 2021– MAY 2026 232.
TABLE 272 TUMOR ABLATION MARKET: EXPANSIONS, JANUARY 2021– MAY 2026 233.
TABLE 273 MEDTRONIC: COMPANY OVERVIEW 234.
TABLE 274 MEDTRONIC: PRODUCTS OFFERED 235.
TABLE 275 MEDTRONIC: PRODUCT APPROVALS, JANUARY 2021−JUNE 2026 236.
TABLE 276 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW 238.
TABLE 277 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED 239.
TABLE 278 EDAP TMS S.A.: COMPANY OVERVIEW 241.
TABLE 279 EDAP TMS S.A.: PRODUCTS OFFERED 242.
TABLE 280 BIOVENTUS INC.: COMPANY OVERVIEW 244.
TABLE 281 BIOVENTUS INC.: PRODUCTS OFFERED 245.
TABLE 282 BIOVENTUS INC.: DEALS 245.
TABLE 283 CONMED CORPORATION: COMPANY OVERVIEW 247.
TABLE 284 CONMED CORPORATION: PRODUCTS OFFERED 248.
TABLE 285 ICECURE MEDICAL LTD.: COMPANY OVERVIEW 250.
TABLE 286 ICECURE MEDICAL LTD.: PRODUCTS OFFERED 251.
TABLE 287 ICECURE MEDICAL LTD.: PRODUCT APPROVALS, JANUARY 2021−JUNE 2026 252.
TABLE 288 ICECURE MEDICAL LTD.: DEALS, JANUARY 2021− JUNE 2026 252.
TABLE 289 ICECURE MEDICAL LTD: EXPANSIONS, JANUARY 2021–JUNE 2026 253.
TABLE 290 ANGIODYNAMICS, INC.: COMPANY OVERVIEW 254.
TABLE 291 ANGIODYNAMICS: PRODUCTS OFFERED 255.
TABLE 292 ANGIODYNAMICS: PRODUCT LAUNCHES, JANUARY 2021−JUNE 2026 256.
TABLE 293 ANGIODYNAMICS: EXPANSIONS, JANUARY 2021–JUNE 2026 256.
TABLE 294 ANGIODYNAMICS: DEALS, JANUARY 2021−JUNE 2026 256.
TABLE 295 VARIAN MEDICAL SYSTEMS, INC.: COMPANY OVERVIEW 257.
TABLE 296 VARIAN MEDICAL SYSTEMS, INC.: PRODUCTS OFFERED 258.
TABLE 297 VARIAN MEDICAL SYSTEMS, INC.: PRODUCT LAUNCHES, JANUARY 2021− JUNE 2026 258.
TABLE 298 VARIAN MEDICAL SYSTEMS, INC.: DEALS, JANUARY 2021− JUNE 2026 258.
TABLE 299 STRYKER: COMPANY OVERVIEW 260.
TABLE 300 STRYKER: PRODUCTS OFFERED 261.
TABLE 301 STRYKER: PRODUCT APPROVALS, JANUARY 2021−JUNE 2026 262.
TABLE 302 STRYKER: EXPANSIONS, JANUARY 2021−JUNE 2026 262.
TABLE 303 CANYON MEDICAL INC. COMPANY OVERVIEW 263.
TABLE 304 CANYON MEDICAL INC.: PRODUCTS OFFERED 263.
TABLE 305 CHONGQING HAIFU MEDICAL TECHNOLOGY CO., LTD: COMPANY OVERVIEW 264.
TABLE 306 CHONGQING HAIFU MEDICAL TECHNOLOGY CO., LTD: PRODUCTS OFFERED 264.
TABLE 307 MERIT MEDICAL SYSTEMS, INC.: COMPANY OVERVIEW 265.
TABLE 308 MERIT MEDICAL SYSTEMS, INC.: PRODUCTS OFFERED 266.
TABLE 309 MERIT MEDICAL SYSTEMS, INC.: DEALS, JANUARY 2021− JUNE 2026 266.
TABLE 310 BAIRD MEDICAL INVESTMENT HOLDINGS LTD.: COMPANY OVERVIEW 267.
TABLE 311 BAIRD MEDICAL INVESTMENT HOLDINGS LTD.: PRODUCTS OFFERED 268.
TABLE 312 BAIRD MEDICAL INVESTMENT HOLDINGS LTD.: EXPANSIONS, JANUARY 2021–JUNE 2026 269.
TABLE 313 QUANTUM SURGICAL: COMPANY OVERVIEW 270.
TABLE 314 QUANTUM SURGICAL: PRODUCTS OFFERED 270.
TABLE 315 QUANTUM SURGICAL: DEALS, JANUARY 2021–JUNE 2026 270.
TABLE 316 THERACLION: COMPANY OVERVIEW 271.
TABLE 317 THERACLION: PRODUCTS OFFERED 271.
TABLE 318 RF MEDICAL CO., LTD.: COMPANY OVERVIEW 272.
TABLE 319 MINIMAX MEDICAL HOLDING GROUP: COMPANY OVERVIEW 273.
TABLE 320 MERMAID MEDICAL: COMPANY OVERVIEW 274.
TABLE 321 MONTERIS: COMPANY OVERVIEW 274.
TABLE 322 SONABLATE CORP.: COMPANY OVERVIEW 275.
TABLE 323 ECO MEDICAL: COMPANY OVERVIEW 276.
TABLE 324 SURGNOVA: COMPANY OVERVIEW 277.
TABLE 325 STARMED CO., LTD.: COMPANY OVERVIEW 278.
TABLE 326 CREO MEDICAL: COMPANY OVERVIEW 279.
TABLE 327 MEDSPHERE SHANGHAI: COMPANY OVERVIEW 280.
TABLE 328 RISK ASSESSMENT: TUMOR ABLATION MARKET 291.
FIGURE 1 TUMOR ABLATION MARKET: YEARS CONSIDERED 31.
FIGURE 2 KEY INSIGHTS & MARKET HIGHLIGHTS 34.
FIGURE 3 GLOBAL TUMOR ABLATION MARKET, 2024–2031 34.
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN TUMOR ABLATION MARKET 35.
FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF TUMOR ABLATION MARKET 36.
FIGURE 6 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN TUMOR ABLATION MARKET, 2026 37.
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 38.
FIGURE 8 INCREASING DEMAND FOR MINIMALLY INVASIVE PROCEDURES TO DRIVE MARKET 39.
FIGURE 9 CONSUMABLES ACCOUNTED FOR LARGEST SHARE OF TUMOR ABLATION MARKET IN 2025 40.
FIGURE 10 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 41.
FIGURE 11 NORTH AMERICA TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD 41.
FIGURE 12 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES 42.
FIGURE 13 TUMOR ABLATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 43.
FIGURE 14 TUMOR ABLATION MARKET: PORTER’S FIVE FORCES ANALYSIS 54.
FIGURE 15 TUMOR ABLATION MARKET SUPPLY CHAIN ANALYSIS 59.
FIGURE 16 VALUE CHAIN ANALYSIS: MAXIMUM VALUE IS ADDED DURING THE MANUFACTURING PHASE 59.
FIGURE 17 TUMOR ABLATION MARKET: ECOSYSTEM ANALYSIS 60.
FIGURE 18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES IN TUMOR ABLATION MARKET 63.
FIGURE 19 INVESTMENT/VENTURE CAPITAL SCENARIO IN TUMOR ABLATION MARKET, 2020–2023 64.
FIGURE 20 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR TUMOR ABLATION MARKET (JANUARY 2016–JUNE 2026) 76.
FIGURE 21 TOP PATENT APPLICANT COUNTRIES FOR TUMOR ABLATION (JANUARY 2016–JUNE 2026) 77.
FIGURE 22 PREMARKET NOTIFICATION: 510(K) APPROVAL FOR MEDICAL DEVICES 87.
FIGURE 23 CANADA: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES 89.
FIGURE 24 EUROPE: CE APPROVAL PROCESS FOR MEDICAL DEVICES 91.
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE CATEGORIES 99.
FIGURE 26 KEY BUYING CRITERIA FOR PROCESS TUMOR ABLATION SYSTEMS 99.
FIGURE 27 NORTH AMERICA: TUMOR ABLATION MARKET SNAPSHOT 137.
FIGURE 28 ASIA PACIFIC: TUMOR ABLATION MARKET SNAPSHOT 168.
FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS IN TUMOR ABLATION MARKET (2021−2025) 215.
FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS IN TUMOR ABLATION MARKET (2025) 216.
FIGURE 31 TUMOR ABLATION MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 219.
FIGURE 32 TUMOR ABLATION MARKET: COMPANY FOOTPRINT 220.
FIGURE 33 TUMOR ABLATION MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 228.
FIGURE 34 EV/EBITDA OF KEY VENDORS 229.
FIGURE 35 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDOR 230.
FIGURE 36 TUMOR ABLATION MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 231.
FIGURE 37 MEDTRONIC: COMPANY SNAPSHOT (2025) 235.
FIGURE 38 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2025) 239.
FIGURE 39 EDAP TMS S.A.: COMPANY SNAPSHOT (2025) 242.
FIGURE 40 BIOVENTUS INC.: COMPANY SNAPSHOT (2025) 244.
FIGURE 41 CONMED CORPORATION: COMPANY SNAPSHOT (2025) 248.
FIGURE 42 ICECURE MEDICAL LTD.: COMPANY SNAPSHOT (2025) 251.
FIGURE 43 ANGIODYNAMICS, INC.: COMPANY SNAPSHOT (2025) 255.
FIGURE 44 VARIAN MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2025) 257.
FIGURE 45 STRYKER: COMPANY SNAPSHOT (2025) 261.
FIGURE 46 MERIT MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2025) 266.
FIGURE 47 BAIRD MEDICAL INVESTMENT HOLDINGS LTD.: COMPANY SNAPSHOT (2025) 268.
FIGURE 48 RESEARCH DESIGN 281.
FIGURE 49 PRIMARY SOURCES 283.
FIGURE 50 BOTTOM-UP APPROACH 284.
FIGURE 51 TOP-DOWN APPROACH 285.
FIGURE 52 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 285.
FIGURE 53 REVENUE SHARE ANALYSIS ILLUSTRATION: MEDTRONIC 286.
FIGURE 54 SUPPLY-SIDE MARKET ESTIMATION: TUMOR ABLATION MARKET (2025) 287.
FIGURE 55 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 288.
FIGURE 56 MARKET DATA TRIANGULATION METHODOLOGY 289.